Ginkgo Bioworks secured a Biopharmaceutical Manufacturing Preparedness Consortium contract through BARDA worth up to $22.2 million to develop cost‑reducing, scalable manufacturing approaches for monoclonal antibodies aimed at filovirus countermeasures. The effort will support production of an anti‑filovirus mAb cocktail discovered at Emory University and integrate innovations across upstream and downstream processes. Ginkgo will lead a consortium including Advanced BioScience Laboratories, Isolere Bio, NeuImmune and ProteoNic BV to advance rapid, domestic mAb production for national biosecurity. The company said the project targets speed and cost improvements to enable deployable therapeutic manufacturing during outbreaks. The award highlights sustained government investment in domestic biologics readiness and underscores industry interest in platform improvements that lower barriers to surge manufacturing for pandemic and biodefense threats.